Jonathan Todd Garland - 25 Apr 2022 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Role
Chief Commercial Officer
Signature
/s/ Valerie Barnett, Attorney-in-Fact for Todd Garland
Issuer symbol
CTKB
Transactions as of
25 Apr 2022
Net transactions value
$0
Form type
4
Filing time
27 Apr 2022, 20:07:54 UTC
Next filing
07 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTKB Stock Option (right to buy) Award $0 +46,971 $0.000000 46,971 25 Apr 2022 Common Stock 46,971 $9.61 Direct F1
transaction CTKB Restricted Stock Units Award $0 +31,217 $0.000000 31,217 25 Apr 2022 Common Stock 31,217 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will vest as follows: 25% of the total shares underlying the option shall vest on April 25, 2023 and 1/48 of the total shares underlying the option shall vest each month thereafter.
F2 Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F3 The shares subject to the RSU Award shall vest quarterly over four years, with 12/48th of the total shares underlying the RSU Award vesting on May 18, 2023 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.